Related coverage linked through entity extraction aliases.
Apr 03, 2026
April 2 biotech value screen names Bicycle Therapeutics, Novavax, and PTC Therapeutics. Novavax earned an A Value Grade; February screens included Arcturus, Emergent, Puma, Rigel, and Sutro.
Jun 01, 2026
The FDA has approved Pfizer's BRAFTOVI for BRAF V600E metastatic colorectal cancer and VEPPANU for ESR1 mutated breast cancer. The oncolytic virus cancer therapy pipeline expands with over 120 companies developing 125+ drugs. Positive late-stage data for other Pfizer oncology programs was also reported.
Feb 25, 2025
Monthly patent reviews from April through December 2025 highlight notable drug discovery IP disclosures across targeted protein degradation, small molecule modulators, and emerging therapeutic targets in oncology, immunology, and neurology.
